Non-steroidal antiandrogens: Synthesis and biological profile of high-affinity ligands for the androgen receptor

@article{Teutsch1994NonsteroidalAS,
  title={Non-steroidal antiandrogens: Synthesis and biological profile of high-affinity ligands for the androgen receptor},
  author={G. Teutsch and F. Goubet and T. Battmann and A. Bonfils and F. Bouchoux and E. C{\'e}r{\`e}de and D. Gofflo and M. Gaillard-Kelly and D. Philibert},
  journal={The Journal of Steroid Biochemistry and Molecular Biology},
  year={1994},
  volume={48},
  pages={111-119}
}
New N-substituted arylthiohydantoin antiandrogens were synthesized. These compounds presented exceptionally high relative binding affinities (RBAs) for the rat androgen receptor (AR): up to 3 times that of testosterone (T) and 100 times the RBAs of non-steroidal antiandrogens such as flutamide, Casodex and Anandron. Furthermore, unlike available markers for AR, they were totally devoid of any binding to the other steroid receptors. RU 59063, the molecule with the highest RBA, was tritiated… Expand
Pharmacological profile of RU 58642, a potent systemic antiandrogen for the treatment of androgen-dependent disorders
TLDR
RU 58642 proved to be significantly more potent than the reference compounds in reducing prostate weight: 3-30 times orally and 3-100 times subcutaneously, and thus the most potent antiandrogen to date to the authors' knowledge. Expand
Receptor affinity and potency of non-steroidal antiandrogens: translation of preclinical findings into clinical activity
TLDR
This clinical trial of bicalutamide confirms the prediction from preclinical studies that a 50 mg dose of bICALutamide would be appropriate for use in patients with advanced prostate cancer, and demonstrates that this bicalUTamide dose is clinically effective when administered as part of CAB. Expand
Preliminary pharmacokinetics and metabolism of novel non-steroidal antiandrogens in the rat: Relation of their systemic activity to the formation of a common metabolite
TLDR
The pharmacological profile of RU 58841 which displays a potent local antiandrogenic activity without systemic effects can be related to its very low propensity to form the N-desalkyl metabolite. Expand
Non-steroidal L-245,976 acts as a classical antiandrogen in vitro
TLDR
A non-steroidal compound N-(4-chlorophenyl)-(Z,Z)-2,3-bis(-cyclopropylmethylene) cyclopentanecarboxamide (L-245976) is described which antagonizes the action of testosterone on DDT1 cells at 10 microM but exhibits little or no effect on cell growth by itself. Expand
Preclinical pharmacology of FL442, a novel nonsteroidal androgen receptor modulator
TLDR
A preclinical proof for FL442 as a promising AR targeted candidate for a further optimization is provided and distribution analyses showed that [(14)CN]FL442 accumulates strongly in the mouse prostate. Expand
Key structural features of nonsteroidal ligands for binding and activation of the androgen receptor.
TLDR
The nonsteroid AR agonists identified from the present studies provided a pool of candidates for further development of selective androgen receptor modulators (SARMs) for androgen therapy and uncovered or confirmed numerous important SARs governing AR binding and functional properties by nonsteroidal molecules, which would be valuable in the future structural optimization of SARMs. Expand
In vitro and in vivo structure-activity relationships of novel androgen receptor ligands with multiple substituents in the B-ring.
TLDR
Novel selective androgen receptor modulators with improved in vivo pharmacological activity can be designed and synthesized based on the structure-activity relationship identified in these studies. Expand
Affinity labeling of the androgen receptor with nonsteroidal chemoaffinity ligands.
TLDR
These isothiocyanate derivatives of R-bicalutamide are the first specific chemoaffinity ligands for the AR, and will provide valuable tools for the molecular characterization of the ligand binding domain of the AR. Expand
Chemical synthesis and biological activities of 16α-derivatives of 5α-androstane-3α,17β-diol as antiandrogens
In our efforts to develop compounds with therapeutic potential as antiandrogens, we synthesized a series of 5alpha-androstane-3alpha,17beta-diol derivatives with a fixed side-chain length ofExpand
General Structure‐Activity Correlations of Antihormones
TLDR
The aim of the present paper is to address the question of what makes the difference in binding behavior between an agonist and an antagonist, in the light of examples taken from the five classes of receptors cited above. Expand
...
1
2
3
4
5
...

References

SHOWING 1-10 OF 35 REFERENCES
ICI 176,334: a novel non-steroidal, peripherally-selective antiandrogen.
  • B. Furr
  • Biology, Medicine
  • Progress in clinical and biological research
  • 1988
TLDR
A new non-steroidal antiandrogen ICI 176,334 (4'-cyano-3-(4-fluorophenylsulphonyl)-2-hydroxy-2-methyl-3'- trifluoromethyl)propion-anilide) has now been discovered which causes regression of the accessory sex organs but does not increase serum concentrations of LH and androgens. Expand
The effect of ketoconazole related imidazole drugs and antiandrogens on [3H] R 1881 binding to the prostatic androgen receptor and [3H]5 alpha-dihydrotestosterone and [3H]cortisol binding to plasma proteins.
TLDR
It is concluded that the primary mode of action of the imidazole drugs is through the inhibition of cytochrome P-450 dependent steroidogenic enzymes with little or no effect on steroid binding proteins. Expand
Specific binding of [3H]-methyltrienolone to both progestin and androgen binding components in human benign prostatic hypertrophy (BPH).
TLDR
The present data clearly show that [ 3 H]-R1881, in the presence of triamcinolone acetonide, can be efficiently used for determination of androgen binding in BPH, a tissue which contains both androgen and progestin binding components. Expand
Clinical profile of a new non-steroidal antiandrogen
  • C. Mahler, L. Denis
  • Medicine
  • The Journal of Steroid Biochemistry and Molecular Biology
  • 1990
TLDR
It is concluded that this compound seems as effective as other antiandrogens, but with improved compliance, and shows less side effects in the management of advanced prostatic cancer. Expand
Synandrogenic and antiandrogenic effect of progestins: comparison with nonprogestational antiandrogens.
TLDR
Of the progestins tested, only medroxyprogesterone acetate (MPA) and megestrol acetate stimulated β-glucuronidase in the kidney, suggesting that androgens and progestin share a common mechanism of action on kidney. Expand
The pure antiandrogen ru 23908 (anandron®), a candidate of choice for the combined antihormonal treatment of prostatic cancer: A review
The nonsteroidal antiandrogen RU 23908 (AnandronR) weakly interacts with the prostatic cytosolic androgen receptor and shows a fast dissociation rate. When administered to immature castrated rats upExpand
Unique steroid congeners for receptor studies.
TLDR
In this study, a simple in vitro system used to define the molecular requirements for a highly specific interaction between a steroid and the receptor corresponding to a single class of hormone is described. Expand
Binding of 7α,17α-Dimethyl-19-Nortestosterone (Mibolerone) to Androgen and Progesterone Receptors in Human and Animal Tissues*
TLDR
The observed differences in binding of [3H]DMNT to rat and calf uterine cytosols suggest the species specificity of progesterone receptors. Expand
A comparative study of the selectivity and efficiency of target tissue uptake of five tritium-labeled androgens in the rat.
TLDR
It is suggested that high affinity androgens labeled with suitable radionuclides--particularly derivatives of mibolerone (Mib) or methyltrienolone (R1881)--may be effective receptor-based imaging agents for androgen target tissues and tumors, even when patients are already receiving hormonal therapy. Expand
Pharmacology of antiandrogens.
TLDR
Based on pharmacological and biochemical backgrounds cyproterone acetate is used in the following indications: Androgen mediated disorders of the skin such as acne, seborrhoea, hirsutism, alopecia, advanced prostatic carcinoma, precocious puberty and male hypersexuality. Expand
...
1
2
3
4
...